Researches and develops active pharmaceutical ingredients (APIs). Produces traditional Chinese medicine derivatives (TCMD). Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
No real growth. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 0.8× for every dollar of annual revenue.
No analyst target is on record for this company.
An investor who bought at the very peak is down 88% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $46.5M a year. A small number, but proof the product has real buyers.
There is $22.4M in the vault; even if every debt were paid off, $21.8M would remain.
It pays out $0.05 per share each year — regular cash for whoever holds the stock.
A loss of $7.8M against $46.5M in annual sales. And on top of that, sales fell from the year before.
Since the drop from its peak, buyer appetite hasn’t come back.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution.